Table 3.

Raw data in terms of r (no. of events) and n (total patients) for eight treatment groups (A-H) in the thrombolytic network meta-analysis.

Study	Treatments evaluated (design)a	rA	nA	rB	nB	rC	nC	rD	nD	rE	nE	rF	nF	rG	nG	rH	nH
1	A B D	1472	20173	652	10344			723	10328
2	A C H	1455	13780			1418	13746									1448	13773
3	A C	9	130			6	123
4	A C	5	63			2	59
5	A C	3	65			3	64
6	A C	887	10396			929	10372
7	A C	7	85			4	86
8	A C	12	147			7	143
9	A C	10	135			5	135
10	A D	4	107					6	109
11	A F	285	2992									270	2994
12	A G	10	203											7	198
13	A H	3	58													2	52
14	A H	3	86													6	89
15	A H	3	58													2	58
16	A H	13	182													11	188
17	B E			522	8488					523	8461
18	B F			356	4921							757	10138
19	B F			13	155							7	169
20	B G			2	26									7	54
21	B G			12	268									16	350
22	B H			5	210											17	211
23	B H			3	138											13	147
24	C G					8	132							4	66
25	C G					10	164							6	166
26	C G					6	124							5	121
27	C H					13	164									10	161
28	C H					7	93									5	90

^aA = SK; B = AtPA; C = t − PA; D = SK + tPA; E = Ten; F = Ret; G = UK; H = ASPAC as referred to in Lu and Ades.³⁰